We hypothesize that rare loss-of-function variants in microglial-expressed genes within the TREM2-TYROBP signaling cascade (PLCG2, TREM2, INPP5D, APOC2) capture a distinct late-onset Alzheimer's disease etiological subtype characterized by dysregulated microglial lipid sensing and enhanced synaptic pruning that is not captured by standard AD polygenic risk scores. This rare variant burden identifies individuals with enhanced microglial-driven neurodegeneration who fall below PRS risk thresholds, representing a 'microglial subtype' that may respond differently to immunomodulatory therapies.
...
We hypothesize that rare loss-of-function variants in microglial-expressed genes within the TREM2-TYROBP signaling cascade (PLCG2, TREM2, INPP5D, APOC2) capture a distinct late-onset Alzheimer's disease etiological subtype characterized by dysregulated microglial lipid sensing and enhanced synaptic pruning that is not captured by standard AD polygenic risk scores. This rare variant burden identifies individuals with enhanced microglial-driven neurodegeneration who fall below PRS risk thresholds, representing a 'microglial subtype' that may respond differently to immunomodulatory therapies. Testable prediction: combining rare variant burden scores from microglial regulatory genes with standard AD PRS will improve area under the ROC curve by >0.05 in independent cohorts and reclassify ~15-20% of cases currently missed by PRS alone.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMID5 mediumValidation: 43%5 supporting / 2 opposing
✓For(5)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
3
MECH 4CLIN 0GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Human and mouse single-nucleus transcriptomics rev…
PLCG2 is expressed and functionally relevant in neurons and astrocytes in addition to microglia; non-microglia…MODERATE▼
PLCG2 is expressed and functionally relevant in neurons and astrocytes in addition to microglia; non-microglial PLCG2 downregulation impairs synaptic function independently, complicating the assignment of TREM2-TYROBP pathway rare variants to a purely microglial mechanism
The protective PLCG2 P522R variant has a moderate effect size (HR ~0.68) and the incremental improvement in LO…MODERATE▼
The protective PLCG2 P522R variant has a moderate effect size (HR ~0.68) and the incremental improvement in LOAD prediction from rare TREM2-TYROBP pathway variants over standard APOE+common-variant PRS is modest; large sequencing studies show these rare variants explain <1% of additional LOAD variance
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Novel Hypotheses: AD PRS Prediction & Rare Variant Integration
Hypothesis 1: Rare Variant Burden Acts as an Effect Modulator on PRS Threshold Effects
Description: Individuals carrying pathogenic rare variants in high-penetrance AD genes (APP, PSEN1, PSEN2) will demonstrate a significantly lower PRS required to reach clinical threshold, suggesting a multiplicative rather than additive genetic model. The mechanistic basis involves shared downstream effects on amyloid processing—rare variants create a "functional deficit" that lowers the polygenic burden needed to exceed the pat
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation: AD Polygenic Risk Scores and Rare Variant Burden Hypotheses
Overview Assessment
The hypotheses demonstrate sophisticated integration of current AD genetics literature and identify genuine gaps in PRS performance. However, several suffer from methodological imprecision, overstated confidence, and citation issues that require scrutiny before acceptance.
Hypothesis 1: Synergistic Epistasis Between Rare Variants and Polygenic Risk
Weaknesses and Challenges
Statistical Power Problem. Detecting gene×gene interaction involving rare variants and PRS req
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Feasibility Assessment: Drug Development & Therapeutic Translation
Hypothesis 4: Conditional Rare Variant Burden Model
Confidence: 0.65 — Most tractable for immediate development
Druggability Assessment
Primary drug targets derived from this model:
| Gene | Function | Druggability | Target Validation Status | |------|----------|--------------|-------------------------| | TREM2 | Microglial survival/activation | ★★★★★ | Highly validated — antibodies in Phase II (AL002) | | ABCA7 | Lipid transport/amyloid clearance | ★★☆☆ | Preclinical — small mol
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Conditional Rare Variant Burden Combined with PRS Identifies Oligogenic Architecture","description":"Current PRS ignores linkage disequilibrium with rare causal variants. A conditional model incorporating rare variant burden scores alongside PRS will significantly improve variance explained by identifying individuals where GWAS signals actually tag rare variant carriers rather than capturing true polygenic signal. This is mechanistically distinct from simple additive models because rare variants and polygenic scores operate through partially overlapping but se